{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013487","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.289431+00:00","generated_at":"2026-06-12T04:15:30.744545+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Q2 net loss widens to $29.6M; zunsemetinib RA data expected Q4 2023","bullets":["Net loss $29.6M vs $20.5M YoY; revenue $1.9M vs $1.5M, driven by licensing royalties.","Cash $210.8M, sufficient through 2025; includes $26.7M from ATM share sale in April 2023.","Zunsemetinib Phase 2b RA trial enrollment completed; topline data expected Q4 2023.","ATI-2138 Phase 1 MAD completed in healthy volunteers; data expected September 2023.","G&A expenses $8.3M include bad debt from EPI Health bankruptcy filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013487","json":"https://secwatch.observer/filing/0001558370-23-013487.json","markdown":"https://secwatch.observer/filing/0001558370-23-013487.md","text":"https://secwatch.observer/filing/0001558370-23-013487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023013487/0001558370-23-013487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023013487/acrs-20230807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:15:30.744545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}